相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Diverse alterations associated with resistance to KRAS(G12C) inhibition
Yulei Zhao et al.
NATURE (2021)
Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers
Takahiro Ito et al.
NATURE GENETICS (2021)
Clinical Acquired Resistance to KRASG12C Inhibition through a novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation
Noritaka Tanaka et al.
CANCER DISCOVERY (2021)
Acquired Resistance to KRASG12C Inhibition in Cancer
M. M. Awad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Meagan B. Ryan et al.
CLINICAL CANCER RESEARCH (2020)
Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
Jenny Y. Xue et al.
NATURE (2020)
Leveraging Systematic Functional Analysis to Benchmark an In Silico Framework Distinguishes Driver from Passenger MEK Mutants in Cancer
Aphrothiti J. Hanrahan et al.
CANCER RESEARCH (2020)
Continuous versus intermittent BRAF and MEK inhibition in patients withBRAF-mutated melanoma: a randomized phase 2 trial
Alain P. Algazi et al.
NATURE MEDICINE (2020)
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
David S. Hong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer
Juergen Wolf et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Hyperactivation of MAPK Signaling Is Deleterious to RAS/RAF-mutant Melanoma
Grace P. Leung et al.
MOLECULAR CANCER RESEARCH (2019)
MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance
Matthew J. Sale et al.
NATURE COMMUNICATIONS (2019)
HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer
Haitang Yang et al.
ONCOGENESIS (2019)
New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
Haitang Yang et al.
FRONTIERS IN ONCOLOGY (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
A view on drug resistance in cancer
Neil Vasan et al.
NATURE (2019)
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Ferdinandos Skoulidis et al.
NATURE REVIEWS CANCER (2019)
Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma
Aayoung Hong et al.
CANCER DISCOVERY (2018)
Trametinib downregulates survivin expression in RB1-positive KRASmutant lung adenocarcinoma cells
Toshiyuki Sumi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS
Chiara Ambrogio et al.
CELL (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells
Otto Kauko et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells
Arun M. Unni et al.
ELIFE (2018)
Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer The SELECT-1 Randomized Clinical Trial
Pasi A. Janne et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Cancer drug addiction is relayed by an ERK2-dependent phenotype switch
Xiangjun Kong et al.
NATURE (2017)
The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib
Kang-Seo Park et al.
CANCER LETTERS (2016)
Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo
Zhen Tao et al.
CLINICAL CANCER RESEARCH (2016)
Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer
Megan L. Hames et al.
LUNG CANCER (2016)
A combinatorial strategy for treating KRAS-mutant lung cancer
Eusebio Manchado et al.
NATURE (2016)
Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer
Hidenori Kitai et al.
CANCER DISCOVERY (2016)
Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles
Eejung Kim et al.
CANCER DISCOVERY (2016)
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)
G. R. Blumenschein et al.
ANNALS OF ONCOLOGY (2015)
Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction
Gatien Moriceau et al.
CANCER CELL (2015)
Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors
Amit Dipak Amin et al.
CANCER RESEARCH (2015)
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology
Donavan T. Cheng et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2015)
Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma
Arun M. Unni et al.
ELIFE (2015)
MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking
Maria E. Arcila et al.
CLINICAL CANCER RESEARCH (2015)
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Mark G. Kris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Chong Sun et al.
NATURE (2014)
Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3
Chong Sun et al.
CELL REPORTS (2014)
Depletion of ERK2 but not ERK1 abrogates oncogenic Ras-induced senescence
Jimin Shin et al.
CELLULAR SIGNALLING (2013)
TGF-beta signaling and epithelial-mesenchymal transition in cancer progression
Yoko Katsuno et al.
CURRENT OPINION IN ONCOLOGY (2013)
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Meghna Das Thakur et al.
NATURE (2013)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
Erick J. Morris et al.
CANCER DISCOVERY (2013)
A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop
K. E. Ware et al.
ONCOGENESIS (2013)
The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models
S. V. Holt et al.
BRITISH JOURNAL OF CANCER (2012)
BRAF(V600) Inhibitor GSK2118436 Targeted Inhibition of Mutant BRAF in Cancer Patients Does Not Impair Overall Immune Competency
David S. Hong et al.
CLINICAL CANCER RESEARCH (2012)
Conversion from the oncogene addiction to drug addiction by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation
Kenichi Suda et al.
LUNG CANCER (2012)
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
Zhao Chen et al.
NATURE (2012)
Fiji: an open-source platform for biological-image analysis
Johannes Schindelin et al.
NATURE METHODS (2012)
Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor
Amelie Clementine Seghers et al.
MELANOMA RESEARCH (2012)
FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor
Vito Guagnano et al.
CANCER DISCOVERY (2012)
STAT3 Mediates Resistance to MEK Inhibitor through MicroRNA miR-17
Bingbing Dai et al.
CANCER RESEARCH (2011)
The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo
Kristen L. Meerbrey et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
Hiroshi Hirai et al.
MOLECULAR CANCER THERAPEUTICS (2010)
KRAS Mutant Lung Cancer Cells Are Differentially Responsive to MEK Inhibitor Due to AKT or STAT3 Activation: Implication for Combinatorial Approach
Young-Kwang Yoon et al.
MOLECULAR CARCINOGENESIS (2010)
High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886)
Jieru Meng et al.
CANCER BIOLOGY & THERAPY (2009)
Oncogenic Activating Mutations Are Associated with Local Copy Gain
Barmak Modrek et al.
MOLECULAR CANCER RESEARCH (2009)
Somatic mutations affect key pathways in lung adenocarcinoma
Li Ding et al.
NATURE (2008)
Characterizing the cancer genome in lung adenocarcinoma
Barbara A. Weir et al.
NATURE (2007)
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
P. J. Roberts et al.
ONCOGENE (2007)
MAP kinase signalling pathways in cancer
A. S. Dhillon et al.
ONCOGENE (2007)
Rational design and characterization of a Rac GTPase-specific small molecule inhibitor
Y Gao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
分享论文
